Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma
The updated PopPK models adequately described ADC and cys-mcMMAF pharmacokinetics. Mild-to-severe renal impairment, mild-to-moderate hepatic impairment (NCI-ODWG), age, ethnicity, region, prior treatments, and prior anti-CD38 therapy did not significantly impact ADC or cys-mcMMAF pharmacokinetics, and combinations showed no meaningful difference in cycle 1 exposure compared with monotherapy.
Authors
- Herbert Struemper (ORCID: https://orcid.org/0000-0003-3011-1572)
- Yu Liu Ho
- Kishore Polireddy
- Geraldine Ferron‐Brady (ORCID: https://orcid.org/0000-0001-5703-8315)
- Theodoros Papathanasiou (ORCID: https://orcid.org/0000-0003-2691-9392)
- Xialin Chen (ORCID: https://orcid.org/0000-0001-7589-7957)
- F. Carreño (ORCID: https://orcid.org/0000-0003-0754-2518)
- Josh Kaullen
- Adekemi B. Taylor (ORCID: https://orcid.org/0000-0002-7373-5660)
Institutions
- Certara (United States) (US)
- Simulation Technologies (United States) (US)
- System Simulation (United Kingdom) (GB)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1007/s40262-025-01508-1
- Citations
- 4
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 7.08